Israel Englander Arrowhead Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 645,604 shares of ARWR stock, worth $12.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

645,604

Previous 529,251 21.98%

Holding current value

$12.7 Million

Previous $13.8 Million 9.14%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $2.25 Million - $3.44 Million	116,353 Added 21.98%	645,604 $12.5 Million
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $4.42 Million - $5.71 Million	202,280 Added 61.86%	529,251 $13.8 Million
Q1 2024 May 15, 2024	BUY	$27.21 - $39.48 $8.9 Million - $12.9 Million	326,971 New	326,971 $9.35 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $16.1 Million - $26.5 Million	-641,001 Reduced 66.12%	328,393 $11.7 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $9.32 Million - $15.2 Million	393,770 Added 68.41%	969,394 $24.6 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $13.9 Million - $20.2 Million	496,910 Added 631.29%	575,624 $23.3 Million
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $1.73 Million - $2.82 Million	-58,464 Reduced 42.62%	78,714 $2.6 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $63,972 - $116,504	-2,302 Reduced 1.65%	137,178 $4.83 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $4.31 Million - $7.61 Million	108,824 Added 354.98%	139,480 $6.42 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $1.01 Million - $1.43 Million	-17,363 Reduced 36.16%	30,656 $2.03 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $1.4 Million - $2.04 Million	23,988 Added 99.82%	48,019 $3 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $378,369 - $549,868	-6,088 Reduced 20.21%	24,031 $1.99 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $117,178 - $172,797	-1,910 Reduced 5.96%	30,119 $2 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $6.85 Million - $13.3 Million	-156,215 Reduced 82.99%	32,029 $2.46 Million
Q3 2020 Nov 16, 2020	BUY	$33.21 - $51.27 $6.25 Million - $9.65 Million	188,244 New	188,244 $8.11 Million
Q1 2020 May 14, 2020	SELL	$20.56 - $63.12 $1.56 Million - $4.79 Million	-75,857 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $1.91 Million - $4.96 Million	68,001 Added 865.59%	75,857 $4.81 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $10.6 Million - $14.1 Million	-405,433 Reduced 98.1%	7,856 $221,000
Q2 2019 Aug 15, 2019	BUY	$17.43 - $28.82 $3.02 Million - $5 Million	173,370 Added 72.26%	413,289 $11 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $12.3 Million - $20.3 Million	-703,916 Reduced 74.58%	239,919 $1.37 Million
Q1 2019 May 14, 2019	BUY	$12.05 - $20.18 $10.1 Million - $16.9 Million	836,894 Added 782.58%	943,835 $17.3 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $1.77 Million - $3.25 Million	-165,120 Reduced 60.69%	106,941 $1.33 Million
Q3 2018 Nov 14, 2018	BUY	$14.0 - $20.3 $3.81 Million - $5.52 Million	272,061 New	272,061 $5.22 Million
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $5.21 Million - $11.5 Million	-817,317 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$3.72 - $7.64 $740,689 - $1.52 Million	-199,110 Reduced 19.59%	817,317 $5.89 Million
Q4 2017 Feb 14, 2018	SELL	$3.14 - $4.5 $802,932 - $1.15 Million	-255,711 Reduced 20.1%	1,016,427 $3.74 Million
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $2.15 Million - $5.51 Million	1,272,138	1,272,138 $5.51 Million

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account